174 related articles for article (PubMed ID: 33506859)
1. Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design.
Domsic RT; Gao S; Laffoon M; Wisniewski S; Zhang Y; Steen V; Lafyatis R; Medsger TA
Rheumatology (Oxford); 2021 Oct; 60(10):4662-4670. PubMed ID: 33506859
[TBL] [Abstract][Full Text] [Related]
2. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
Domsic RT; Medsger TA; Gao S; Laffoon M; Huang S; Wisniewski S; Spino C; Steen V; Lafyatis R; Khanna D
Rheumatology (Oxford); 2023 Apr; 62(4):1543-1551. PubMed ID: 36031807
[TBL] [Abstract][Full Text] [Related]
3. Time to diagnosis in systemic sclerosis: is sex a factor?
Hudson M; Thombs B; Baron M;
Arthritis Rheum; 2009 Feb; 61(2):274-8. PubMed ID: 19177534
[TBL] [Abstract][Full Text] [Related]
4. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
5. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database.
Carreira PE; Carmona L; Joven BE; Loza E; Andreu JL; Riemekasten G; Vettori S; Balbir-Gurman A; Airò P; Walker UA; Damjanov N; Matucci-Cerinic M; Ananieva LP; Rednic S; Czirják L; Distler O; Farge D; Hesselstrand R; Corrado A; Caramaschi P; Tikly M; Allanore Y;
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):68-75. PubMed ID: 30277860
[TBL] [Abstract][Full Text] [Related]
6. Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry.
Delisle VC; Hudson M; Baron M; Thombs BD; And The Canadian Scleroderma Research Group A
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-10-4. PubMed ID: 24144459
[TBL] [Abstract][Full Text] [Related]
7. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
[TBL] [Abstract][Full Text] [Related]
8. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
Wannarong T; Muangchan C
Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
[TBL] [Abstract][Full Text] [Related]
9. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
Lescoat A; Huang S; Carreira PE; Siegert E; de Vries-Bouwstra J; Distler JHW; Smith V; Del Galdo F; Anic B; Damjanov N; Rednic S; Ribi C; Bancel DF; Hoffmann-Vold AM; Gabrielli A; Distler O; Khanna D; Allanore Y;
JAMA Dermatol; 2023 Aug; 159(8):837-847. PubMed ID: 37378994
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study.
Foocharoen C; Peansukwech U; Mahakkanukrauh A; Suwannaroj S; Pongkulkiat P; Khamphiw P; Nanagara R
Int J Rheum Dis; 2020 Jul; 23(7):945-957. PubMed ID: 32420701
[TBL] [Abstract][Full Text] [Related]
12. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.
Herrick AL; Peytrignet S; Lunt M; Pan X; Hesselstrand R; Mouthon L; Silman AJ; Dinsdale G; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk MC; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jobanputra P; Jordan AC; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov NS; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman SM; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
Ann Rheum Dis; 2018 Apr; 77(4):563-570. PubMed ID: 29306872
[TBL] [Abstract][Full Text] [Related]
13. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.
Maurer B; Graf N; Michel BA; Müller-Ladner U; Czirják L; Denton CP; Tyndall A; Metzig C; Lanius V; Khanna D; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1124-31. PubMed ID: 24981642
[TBL] [Abstract][Full Text] [Related]
14. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.
Skaug B; Khanna D; Swindell WR; Hinchcliff ME; Frech TM; Steen VD; Hant FN; Gordon JK; Shah AA; Zhu L; Zheng WJ; Browning JL; Barron AMS; Wu M; Visvanathan S; Baum P; Franks JM; Whitfield ML; Shanmugam VK; Domsic RT; Castelino FV; Bernstein EJ; Wareing N; Lyons MA; Ying J; Charles J; Mayes MD; Assassi S
Ann Rheum Dis; 2020 Mar; 79(3):379-386. PubMed ID: 31767698
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis.
Solanki KK; Hor C; Chang WSJ; Frampton C; White DHN
Int J Rheum Dis; 2017 Jun; 20(6):767-773. PubMed ID: 28261995
[TBL] [Abstract][Full Text] [Related]
16. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.
Shand L; Lunt M; Nihtyanova S; Hoseini M; Silman A; Black CM; Denton CP
Arthritis Rheum; 2007 Jul; 56(7):2422-31. PubMed ID: 17599771
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
[TBL] [Abstract][Full Text] [Related]
18. Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort.
Hughes M; Huang S; Alegre-Sancho JJ; Carreira PE; Engelhart M; Hachulla E; Henes J; Kerzberg E; Pozzi MR; Riemekasten G; Smith V; Szücs G; Vanthuyne M; Zanatta E; Distler O; Gabrielli AG; Hoffmann-Vold AM; Steen VD; Khanna D;
Rheumatology (Oxford); 2023 Feb; 62(SI):SI54-SI63. PubMed ID: 35731139
[TBL] [Abstract][Full Text] [Related]
19. Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis.
Ledoult E; Launay D; Béhal H; Mouthon L; Pugnet G; Lega JC; Agard C; Allanore Y; Jego P; Fauchais AL; Harlé JR; Berthier S; Aouba A; Mekinian A; Diot E; Truchetet ME; Boulon C; Duhamel A; Hachulla E; Sobanski V;
Arthritis Res Ther; 2020 Feb; 22(1):30. PubMed ID: 32070422
[TBL] [Abstract][Full Text] [Related]
20. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
Amjadi S; Maranian P; Furst DE; Clements PJ; Wong WK; Postlethwaite AE; Khanna PP; Khanna D;
Arthritis Rheum; 2009 Aug; 60(8):2490-8. PubMed ID: 19644851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
